This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Four hundred and eight (408) eligible subjects at up to twenty-five (25) study sites will be randomized 1:1 for treatment using the AGN1 LOEP SV Kit (Intervention Group) or PMMA bone cement (Active Control Group). 1. Intervention Group - receives vertebral augmentation of the target VCF(s) using the AGN1 LOEP SV Kit 2. Active Control Group - receives vertebral augmentation of the target VCF(s) using either Stryker VertaPlex HV or Medtronic Kyphon HV-R. Follow-up visits will be conducted at 7 days, 28 days, 3 months, 12 months and 24 months after the procedure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
408
The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
High viscosity PMMA bone cement will be used for vertebral augmentation.
Alabama Clinical Therapeutics
Birmingham, Alabama, United States
RECRUITINGElite Pain and Spine Institute
Mesa, Arizona, United States
RECRUITINGMayo Clinic
Phoenix, Arizona, United States
WITHDRAWNGW Medical Faculty Associates
Washington D.C., District of Columbia, United States
WITHDRAWNOrlando Neurosurgery (Conquest Research)
Orlando, Florida, United States
RECRUITINGCleveland Clinic Florida
Stuart, Florida, United States
RECRUITINGRush University Medical Center
Chicago, Illinois, United States
RECRUITINGNorthShore University HealthSystem
Evanston, Illinois, United States
RECRUITINGDuly Health / NextStage Clinical Research
Naperville, Illinois, United States
WITHDRAWNUniversity of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas, United States
RECRUITING...and 9 more locations
Change in VCF-related Pain as measured by a 100 mm Visual Analogue Scale (VAS)
Change in VCF-related pain by \> 20 mm from baseline as measured by a 100 mm Visual Analogue Scale (VAS) where 0mm is no pain, and 100mm is worst pain possible.
Time frame: 24 months
Change in function
change of function from baseline as measured by the Oswestry Disability Index (ODI)
Time frame: 24 months
Radiographic evidence of implant resorption (Intervention Group only)
change in resorption from procedure as assessed by independent radiographer
Time frame: 24 months
Radiographic evidence of bone formation (Intervention Group only)
change in bone formation from procedure as assessed by independent radiographer
Time frame: 24 months
Adverse events
Occurrence of device-related serious adverse events, device-related adverse events or serious adverse events categorized as failure or surgical intervention at the target level occurring post-treatment
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.